Feasibility Trial Testing the Bionic Pancreas With ZP4207
Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207
(dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes
mellitus.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207